Allergies vs Cold Symptoms: How to Determine What’s Making You Miserable
Aches and pains. Pain (think: body aches and a sore throat) is also a tip off that you’re dealing with a virus like a cold.
FDA recalls over 89K bottles of nasal spray that may cause ‘adverse’ medical effects during flu season, throw out ASAP
The U.S. Food and Drug Administration is recalling 89,312 bottles of NasoGel nasal spray because the product might cause ...
Hosted on MSN3d
What Is a Sinus Headache?
For some people, the classic symptoms of a sinus infection, including nasal congestion and discharge, are also accompanied by ...
pulmonologyadvisor3d
Nasal Spray Formulation of Bumetanide Under FDA Review
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
Over 89,000 Bottles of Nasal Spray Recalled By FDA—What to Know
There’s another recall to be aware of right now, and it involves nose spray. NeilMed Pharmaceuticals Inc., the manufacturer of NasoGel Spray, has issued an international recall of 89,312 of its sprays ...
Mucus in nose and throat: How to stop post-nasal drip at home
Post-nasal drip occurs when excess mucus accumulates in the back of the throat or nose, primarily due to allergies, ...
Keymed’s Stapokibart approved by NMPA for seasonal allergic rhinitis
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...
FDA Greenlights U.S. Clinical Trial for New Nasal COVID-19 Vaccine
The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...
Keymed Biosciences Inc.: Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental ...
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of ...